A Mab A Case Study In Bioprocess Development

This content is suitable for a bioprocess engineering blog, a technical whitepaper, or an educational slide deck.

CEX (bind-elute) → AEX (flow-through)

The final train: . CEX removed aggregates to <0.8%; AEX removed residual DNA (<10 pg/dose) and HCP (<5 ppm). A Mab A Case Study In Bioprocess Development

This case study demonstrates a successful, scalable, and compliant bioprocess for a therapeutic mAb, achieving: This content is suitable for a bioprocess engineering

3.1 Harvest and Clarification

Monoclonal antibodies (mAbs) have become the cornerstone of modern biopharmaceuticals, treating everything from oncology and autoimmune disorders to infectious diseases. However, the journey from a hybridoma cell line to a commercially viable product is fraught with complexity. For every successful mAb on the market, there are hundreds of failed attempts—not due to lack of efficacy, but often due to poor bioprocess development. This case study demonstrates a successful, scalable, and